17:07 , May 11, 2018 |  BC Week In Review  |  Financial News

InflaRx raises $51M follow-on

Inflammatory diseases company InflaRx N.V. (NASDAQ:IFRX) raised $51 million on May 3 through the sale of 1.5 million shares at $34 in a follow-on underwritten by J.P. Morgan, Leerink, BMO Capital Markets and SunTrust Robinson...
21:23 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

InflaRx reports Phase IIa data of mAb against C5a for rare inflammatory skin disease

In September, InflaRx N.V. (NASDAQ:IFRX) reported data from a Phase IIa trial in 12 patients with moderate to severe hidradenitis suppurativa showing that IV IFX-1 (CaCP29) led to response rates of 75% at week 8...
20:43 , Nov 10, 2017 |  BC Week In Review  |  Financial News

InflaRx prices $100M IPO

InflaRx N.V. (NASDAQ:IFRX) raised $100 million on Nov. 8 through the sale of 6.7 million shares at $15 in an IPO underwritten by JPMorgan, Leerink and BMO Capital Markets. The share price is at the...
19:12 , Nov 8, 2017 |  BC Extra  |  Financial News

InflaRx prices $100M IPO

InflaRx N.V. (NASDAQ:IFRX) raised $100 million on Wednesday through the sale of 6.7 million shares at $15 in an IPO underwritten by JPMorgan, Leerink and BMO Capital Markets. The share price is at the midpoint...
21:14 , Oct 13, 2017 |  BC Week In Review  |  Financial News

InflaRx raises $55M in series D

InflaRx GmbH (Jena, Germany) raised $55 million in a series D round from Bain Capital Life Sciences, Cormorant Asset Management, RA Capital and undisclosed funds managed by a U.S. firm. InflaRx said the round included...
18:04 , Oct 13, 2017 |  BC Extra  |  Financial News

InflaRx raises $55M in series D round

InflaRx GmbH (Jena, Germany) raised $55 million in a series D round from Bain Capital Life Sciences, Cormorant Asset Management, RA Capital and undisclosed funds managed by a U.S. firm. InflaRx said the round included...
22:04 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

IFX-1: Ph II started

InflaRx began an open-label, Greek Phase II trial to evaluate once-weekly IV IFX-1 for 8 weeks in 12 patients who have failed previous antibiotic or biological treatment. InflaRx GmbH, Jena, Germany  Product: CaCP29, IFX-1  Business: Dermatology  Molecular target: Complement...
07:00 , Jul 21, 2016 |  BC Extra  |  Financial News

InflaRx raises EUR 31M in series C

InflaRx GmbH (Jena, Germany) raised EUR 31 million ($34.3 million) in a series C round. New investors included Staidson Hongkong Investment Co. Ltd., international industrial investors and family offices. Existing investors also participated. Last month,...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

CaCP29: Phase II started

InflaRx began the double-blind, placebo-controlled, German Phase II CARDIAC trial to evaluate IFX-1 in 100 patients undergoing complex cardiac surgery. The surgery is defined as invasive open heart and/or aortic trunk surgical procedures requiring cardiopulmonary...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

CaCP29: Phase IIa data

InflaRx said top-line data from the double-blind, placebo-controlled, dose-escalation, German Phase IIa SCIENS trial in 72 patients with early septic organ dysfunction showed that IV IFX-1 met the primary endpoints of safety, pharmacokinetics and pharmacodynamics....